Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q1 2021 · 10-Q
Revenue$7.25M$7.25Mno prior Q1 2020 on file Net Income-$9.02M-$9.02MN/M vs Q1 2020 EPS Diluted-$0.28-$0.28N/M vs Q1 2020 Operating Income-$9,135,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,727,000— Margins · derivedOperating margin-126.1%
Net margin-124.5%
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end